Comparison
3 Methylglutaconic Aciduria C3696376 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between 3 Methylglutaconic Aciduria and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria C3696376
A metabolic disorder causing abnormal acid buildup affecting multiple body systems including the brain. Severity varies widely among affected individuals. Care focuses on symptom management and metabolic support.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
3 Methylglutaconic Aciduria C3696376
0-10
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria C3696376
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria C3696376
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria C3696376
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
3 Methylglutaconic Aciduria C3696376
metabolic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
3 Methylglutaconic Aciduria C3696376
metabolic
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-C3696376 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria C3696376 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Metabolic decompensation | May include episodes of abnormal organic-acid buildup affecting multiple systems, including the brain. | Not primarily described as an organic aciduria; metabolic crises are not established. | High |
| Developmental or neurologic features | Neurologic involvement can occur, but severity and features vary widely. | Developmental delay and neurologic features are commonly described. | Moderate |
| Kidney involvement | Kidney disease is not established from the supplied description. | Potential kidney involvement is described and may need monitoring. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria C3696376 when
Childhood metabolic presentation
Onset is described within ages 0–10 and the category is metabolic.
Moderate
Suspected organic acid accumulation
The condition is defined by abnormal acid buildup rather than a chromosomal deletion.
High
Severe multisystem course
Supplied severity is severe, although individual severity varies widely.
Low
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Congenital developmental pattern
It is a congenital genetic deletion syndrome with developmental and neurologic features.
Moderate
Possible renal involvement
Potential kidney involvement supports consideration of this syndrome.
Moderate
Chromosomal deletion evidence
A recurrent 17q12 deletion is the defining etiology when confirmed.
High
How key tests differ
| Test | 3 Methylglutaconic Aciduria C3696376 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Urine organic acid analysis | May show abnormal organic acids, including 3-methylglutaconic acid; no cutoff is supplied. | No characteristic organic-acid pattern is established. | An abnormal result supports metabolic evaluation but is not itself a complete diagnosis. |
| Chromosomal microarray or targeted deletion testing | A 17q12 deletion is not the described cause. | May identify a recurrent deletion on chromosome 17. | Genetic confirmation distinguishes the deletion syndrome; clinical correlation remains necessary. |
| Renal assessment | No specific renal abnormality is established here. | Monitoring may detect potential kidney involvement. | Abnormal kidney findings require clinician interpretation and do not alone confirm either condition. |
Prognosis comparison
3 Methylglutaconic Aciduria C3696376
- Outcome
- Chronic course with widely variable severity; exact outcomes are not established.
- Factors
- Extent of metabolic and neurologic involvement may influence course, but predictors are not supplied.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- Chronic congenital condition, generally described as moderate, with variable individual needs.
- Factors
- Developmental, neurologic, and possible kidney involvement may affect outlook.
Time frame: Long-term; precise timelines are not established.
Etiology, severity, affected systems, and response to supportive care require clinician assessment.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic complications | Brain involvement may occur with widely variable severity. Neurologic features and developmental delay may occur. Specific complications and frequencies are not established by the supplied data. |
| Metabolic instability | Abnormal acid buildup may require metabolic support and symptom management. Metabolic instability is not established as a core feature. Management details and treatment doses should not be inferred. |
| Kidney complications | Not established from the available description. Potential kidney involvement may require regular monitoring. The presence, timing, and severity of renal disease are not specified. |
Patient education highlights
- HighDifferent causes
One is a metabolic disorder; the other is a chromosomal deletion. Neither is communicable.
- HighVariable course
Severity varies, especially in 3-methylglutaconic aciduria. Monitoring and supportive care are individualized.
- MediumTest meaning
An abnormal laboratory or genetic result needs clinician interpretation and does not replace a full diagnosis.